BillionToOne

Oncology Specialist

San Antonio, Texas, United States

Not SpecifiedCompensation
Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Healthcare, PharmaceuticalIndustries

Requirements

The Oncology Specialist should possess scientific and clinical expertise in oncology, with a strong understanding of liquid biopsy technologies and cancer diagnostics. Experience in sales and market development within the oncology field is preferred, along with the ability to cultivate relationships with oncologists and the broader cancer care community.

Responsibilities

The Oncology Specialist will be responsible for increasing revenue and driving market development through direct sales to individual Oncologists, creating and implementing a strategic sales plan, and fostering relationships with oncologists and other members of the extended cancer care community in South Texas (San Antonio-Rio Grande Valley).

Skills

Liquid Biopsy
Cancer Diagnostics
Sales
Market Development
Relationship Building
Strategic Planning

BillionToOne

Molecular diagnostics for prenatal and oncology testing

About BillionToOne

BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases at a single base-pair resolution, enabling the identification of minute variations in DNA. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which tracks the effectiveness of that therapy. Unlike many competitors, BillionToOne emphasizes accuracy, efficiency, and accessibility in molecular testing, providing diagnostic services directly to healthcare providers. Their goal is to positively impact healthcare by making molecular testing more reliable and available to everyone.

Menlo Park, CaliforniaHeadquarters
2016Year Founded
$380.2MTotal Funding
SERIES_DCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Competitive pay
Retirement savings package
Parental leave
Free snacks & lunches
Medical, dental, & vision premiums
On campus perks
Free-on-site EV charging

Risks

Emerging biotech startups could threaten BillionToOne's market share.
Rapid technological advancements may render their current technology obsolete.
Expansion into new facilities may face operational challenges or delays.

Differentiation

BillionToOne's QCT technology detects DNA variations at single base-pair resolution.
Their UNITY Fetal Antigen NIPT is the first US cfDNA test for fetal antigen genotyping.
They replace invasive amniocentesis with a safe, affordable blood test for prenatal screening.

Upsides

BillionToOne achieved a billion-dollar valuation with a $130 million funding round.
Their new Austin facility will create 1,000 jobs, boosting production and local economy.
Recognition as Diagnostics Company of the Year highlights their industry leadership.

Land your dream remote job 3x faster with AI